Medicis Pharmaceutical Corporation announces the launch of the Plexion Cleansing Cloth, an innovative topical skin medication designed for the management of acne, rosacea and seborrheic dermatitis. The medicated cloth moisturizes as it cleans and uses a combination of 10% sodium sulfacetamide and 5% sulfur to provide a safe and effective treatment to infected areas. The cloth is gentle on the skin, easy to apply and reports a low incidence of local irritation. As the first prescription cloth on the market and the most recent advance in the Plexion line of dermatologic interventions, the Plexion Cleansing Cloth provides an alternative skin cleansing therapy to traditional prescription cleansers. The Plexion Cleansing Cloth is available by prescription only and includes 30 individually foil wrapped cloths per box. The product is contraindicated for patients with hypersensitivity to sulfur and sulfonamides and patients with kidney disease. For more information on the Plexion Cleansing Cloth and other Medicis skin medications, please visit the company’s Web site at www.medicis.com. Proprietary Spray Delivery System for Wound Healing Healthpoint introduces the manufacture and release of Accuzyme Spray, their second product to feature the exclusive non-aerosol, pump spray delivery system. Accuzyme (Papain, Urea) is indicated for the effective treatment of acute and chronic wounds such as pressure, ulcer, varicose veins, diabetic ulcers, postoperative wounds and burns. Previously, the product was available in ointment form only and applied with a cotton swab or tongue depressor, often causing unnecessary pain for the patient and disturbance of the wound bed. Now, through this patent pending mechanism, Accuzyme can be dispensed through a liquid spray application. The medication is administered smoothly, evenly, and in controlled amounts — a benefit to both the patient and the caregiver. Accuzyme is a safe, non-irritating medication with a proven reputation in wound debridement that is widely used in hospitals, wound-care centers and long term care facilities. For more information on the Accuzyme spray or other Healthpoint products, please call (800)-841-8227 or visit www.healthpoint.com. New Collaboration for Myrac Glades Pharmaceuticals, LLC, a division of Stiefel Laboratories, Inc., has partnered with Ranbaxy Pharmaceuticals to manufacture and distribute Myrac tablets, a new oral pharmaceutical product for the treatment of acne. In January 2004, Ranbaxy Pharmaceutical received approval from the FDA to commercialize Minocycline Hydrochloride Tablets, USP and to supply Myrac tablets to Glades Pharmaceutical for promotion and distribution. According to Glades Pharmaceutical President Jeffrey S. Thompson, this synergy is “mutually beneficial to both organizations and of value to prescribers and patients.” The tablets contain amounts of Minocycline Hydrochloride that equal 50 mg, 75 mg, and 100 mg of minocycline and will offer a therapy alternative to Dynacine Tablets, a major competitor in this market. For more information on Myrac tablets, please call 1-888-445-2337. New Intensive Kinerase Treatment Kinerase recently developed C6 Peptide Intensive Treatment, a new skincare product that will complement the Kinerase anti-aging technology system. C6 Peptide Intensive Treatment utilizes a formula of six amino acids to help protect the skin, boost collagen production and reduce the appearance of wrinkles. The product contains several neutralizing agents such as Vitamin C and Vitamin E that help protect against damaging free radicals as well as Green Tea Extract that helps to soothe the skin. The treatment is non-irritating and safe for most skin types. Kinerase C6 Peptide Intensive Treatment is recom-mended for use in conjunction with Kinerase Cream/Lotion or SPF 15. For more information about Kinerase C6 Peptide Intensive Treatment or other Kinerase products please visit www.kinerase.com or call 1-800-826-9755. Advanced Cancer Screening Tool DigitalDerm, Inc. presents the MoleMapCD, a technological advance in dermatologic screening and testing. The MoleMapCD is a CD-ROM-based medical record that uses photographic images of patients to track changes in moles. Developed through a collaboration with the Duke University Comprehensive Cancer Center, MoleMapCD is the first fully digital baseline system developed specifically to enhance early diagnosis of melanoma. The development of the CD requires a medical photographer to take pictures of the patient and produce a mole-map by digitizing these images to a CD-ROM. The CD is then sent to the physician and a copy is sent to the patient so that he or she can monitor changes. The test is recognized by the American Medical Association as a reimbursable medical expense. In addition, it is covered by some national insurance carriers. For more information on this product and DigitalDerm, Inc., please visit www.digitalderm.com.
ADVERTISEMENT
New Prescription Cleansing Cloth
Medicis Pharmaceutical Corporation announces the launch of the Plexion Cleansing Cloth, an innovative topical skin medication designed for the management of acne, rosacea and seborrheic dermatitis. The medicated cloth moisturizes as it cleans and uses a combination of 10% sodium sulfacetamide and 5% sulfur to provide a safe and effective treatment to infected areas. The cloth is gentle on the skin, easy to apply and reports a low incidence of local irritation. As the first prescription cloth on the market and the most recent advance in the Plexion line of dermatologic interventions, the Plexion Cleansing Cloth provides an alternative skin cleansing therapy to traditional prescription cleansers. The Plexion Cleansing Cloth is available by prescription only and includes 30 individually foil wrapped cloths per box. The product is contraindicated for patients with hypersensitivity to sulfur and sulfonamides and patients with kidney disease. For more information on the Plexion Cleansing Cloth and other Medicis skin medications, please visit the company’s Web site at www.medicis.com. Proprietary Spray Delivery System for Wound Healing Healthpoint introduces the manufacture and release of Accuzyme Spray, their second product to feature the exclusive non-aerosol, pump spray delivery system. Accuzyme (Papain, Urea) is indicated for the effective treatment of acute and chronic wounds such as pressure, ulcer, varicose veins, diabetic ulcers, postoperative wounds and burns. Previously, the product was available in ointment form only and applied with a cotton swab or tongue depressor, often causing unnecessary pain for the patient and disturbance of the wound bed. Now, through this patent pending mechanism, Accuzyme can be dispensed through a liquid spray application. The medication is administered smoothly, evenly, and in controlled amounts — a benefit to both the patient and the caregiver. Accuzyme is a safe, non-irritating medication with a proven reputation in wound debridement that is widely used in hospitals, wound-care centers and long term care facilities. For more information on the Accuzyme spray or other Healthpoint products, please call (800)-841-8227 or visit www.healthpoint.com. New Collaboration for Myrac Glades Pharmaceuticals, LLC, a division of Stiefel Laboratories, Inc., has partnered with Ranbaxy Pharmaceuticals to manufacture and distribute Myrac tablets, a new oral pharmaceutical product for the treatment of acne. In January 2004, Ranbaxy Pharmaceutical received approval from the FDA to commercialize Minocycline Hydrochloride Tablets, USP and to supply Myrac tablets to Glades Pharmaceutical for promotion and distribution. According to Glades Pharmaceutical President Jeffrey S. Thompson, this synergy is “mutually beneficial to both organizations and of value to prescribers and patients.” The tablets contain amounts of Minocycline Hydrochloride that equal 50 mg, 75 mg, and 100 mg of minocycline and will offer a therapy alternative to Dynacine Tablets, a major competitor in this market. For more information on Myrac tablets, please call 1-888-445-2337. New Intensive Kinerase Treatment Kinerase recently developed C6 Peptide Intensive Treatment, a new skincare product that will complement the Kinerase anti-aging technology system. C6 Peptide Intensive Treatment utilizes a formula of six amino acids to help protect the skin, boost collagen production and reduce the appearance of wrinkles. The product contains several neutralizing agents such as Vitamin C and Vitamin E that help protect against damaging free radicals as well as Green Tea Extract that helps to soothe the skin. The treatment is non-irritating and safe for most skin types. Kinerase C6 Peptide Intensive Treatment is recom-mended for use in conjunction with Kinerase Cream/Lotion or SPF 15. For more information about Kinerase C6 Peptide Intensive Treatment or other Kinerase products please visit www.kinerase.com or call 1-800-826-9755. Advanced Cancer Screening Tool DigitalDerm, Inc. presents the MoleMapCD, a technological advance in dermatologic screening and testing. The MoleMapCD is a CD-ROM-based medical record that uses photographic images of patients to track changes in moles. Developed through a collaboration with the Duke University Comprehensive Cancer Center, MoleMapCD is the first fully digital baseline system developed specifically to enhance early diagnosis of melanoma. The development of the CD requires a medical photographer to take pictures of the patient and produce a mole-map by digitizing these images to a CD-ROM. The CD is then sent to the physician and a copy is sent to the patient so that he or she can monitor changes. The test is recognized by the American Medical Association as a reimbursable medical expense. In addition, it is covered by some national insurance carriers. For more information on this product and DigitalDerm, Inc., please visit www.digitalderm.com.
Medicis Pharmaceutical Corporation announces the launch of the Plexion Cleansing Cloth, an innovative topical skin medication designed for the management of acne, rosacea and seborrheic dermatitis. The medicated cloth moisturizes as it cleans and uses a combination of 10% sodium sulfacetamide and 5% sulfur to provide a safe and effective treatment to infected areas. The cloth is gentle on the skin, easy to apply and reports a low incidence of local irritation. As the first prescription cloth on the market and the most recent advance in the Plexion line of dermatologic interventions, the Plexion Cleansing Cloth provides an alternative skin cleansing therapy to traditional prescription cleansers. The Plexion Cleansing Cloth is available by prescription only and includes 30 individually foil wrapped cloths per box. The product is contraindicated for patients with hypersensitivity to sulfur and sulfonamides and patients with kidney disease. For more information on the Plexion Cleansing Cloth and other Medicis skin medications, please visit the company’s Web site at www.medicis.com. Proprietary Spray Delivery System for Wound Healing Healthpoint introduces the manufacture and release of Accuzyme Spray, their second product to feature the exclusive non-aerosol, pump spray delivery system. Accuzyme (Papain, Urea) is indicated for the effective treatment of acute and chronic wounds such as pressure, ulcer, varicose veins, diabetic ulcers, postoperative wounds and burns. Previously, the product was available in ointment form only and applied with a cotton swab or tongue depressor, often causing unnecessary pain for the patient and disturbance of the wound bed. Now, through this patent pending mechanism, Accuzyme can be dispensed through a liquid spray application. The medication is administered smoothly, evenly, and in controlled amounts — a benefit to both the patient and the caregiver. Accuzyme is a safe, non-irritating medication with a proven reputation in wound debridement that is widely used in hospitals, wound-care centers and long term care facilities. For more information on the Accuzyme spray or other Healthpoint products, please call (800)-841-8227 or visit www.healthpoint.com. New Collaboration for Myrac Glades Pharmaceuticals, LLC, a division of Stiefel Laboratories, Inc., has partnered with Ranbaxy Pharmaceuticals to manufacture and distribute Myrac tablets, a new oral pharmaceutical product for the treatment of acne. In January 2004, Ranbaxy Pharmaceutical received approval from the FDA to commercialize Minocycline Hydrochloride Tablets, USP and to supply Myrac tablets to Glades Pharmaceutical for promotion and distribution. According to Glades Pharmaceutical President Jeffrey S. Thompson, this synergy is “mutually beneficial to both organizations and of value to prescribers and patients.” The tablets contain amounts of Minocycline Hydrochloride that equal 50 mg, 75 mg, and 100 mg of minocycline and will offer a therapy alternative to Dynacine Tablets, a major competitor in this market. For more information on Myrac tablets, please call 1-888-445-2337. New Intensive Kinerase Treatment Kinerase recently developed C6 Peptide Intensive Treatment, a new skincare product that will complement the Kinerase anti-aging technology system. C6 Peptide Intensive Treatment utilizes a formula of six amino acids to help protect the skin, boost collagen production and reduce the appearance of wrinkles. The product contains several neutralizing agents such as Vitamin C and Vitamin E that help protect against damaging free radicals as well as Green Tea Extract that helps to soothe the skin. The treatment is non-irritating and safe for most skin types. Kinerase C6 Peptide Intensive Treatment is recom-mended for use in conjunction with Kinerase Cream/Lotion or SPF 15. For more information about Kinerase C6 Peptide Intensive Treatment or other Kinerase products please visit www.kinerase.com or call 1-800-826-9755. Advanced Cancer Screening Tool DigitalDerm, Inc. presents the MoleMapCD, a technological advance in dermatologic screening and testing. The MoleMapCD is a CD-ROM-based medical record that uses photographic images of patients to track changes in moles. Developed through a collaboration with the Duke University Comprehensive Cancer Center, MoleMapCD is the first fully digital baseline system developed specifically to enhance early diagnosis of melanoma. The development of the CD requires a medical photographer to take pictures of the patient and produce a mole-map by digitizing these images to a CD-ROM. The CD is then sent to the physician and a copy is sent to the patient so that he or she can monitor changes. The test is recognized by the American Medical Association as a reimbursable medical expense. In addition, it is covered by some national insurance carriers. For more information on this product and DigitalDerm, Inc., please visit www.digitalderm.com.
